Special Registrations for Telemedicine and Limited State Telemedicine Registrations
The DEA has finalized rules for special telemedicine registrations, allowing controlled substance prescribing without an in-person visit under certain conditions, but with new compliance requirements.
Aforeworn detected this change in the Telehealth Cross-State Licensing space on July 5, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Registrations open now; COVID-19 flexibilities expire 90 days after rule effective date (likely April 2025).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Telehealth Cross-State Licensing continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New special registration pathways for telemedicine prescribing of controlled substances, replacing the COVID-19 flexibilities; requires registration and compliance with specific practice and documentation standards.
Who it affects
Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers
What you must do
Evaluate whether to apply for a special registration or adjust prescribing practices to comply with new rules.
Deadline
Registrations open now; COVID-19 flexibilities expire 90 days after rule effective date (likely April 2025).
Never miss a change like this again
Aforeworn watches Telehealth Cross-State Licensing around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Telehealth Cross-State Licensing
- Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program; Correction
- Risk-Informed, Technology-Inclusive Regulatory Framework for Advanced Reactors
- Medicare Program; Contract Year 2027 and Certain Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program
- Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements
- Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; and Other Policy Changes